Penn’s one-stop solution for technology commercialization and entrepreneurship
I’m a Faculty Member or Researcher
I’m with a Company
I’m an Entrepreneur
I want to:
Translating Discoveries
PCI helps to translate discoveries and ideas created at the University of Pennsylvania into new products and businesses for societal benefit.
We actively facilitate a broad range of technology development connections between Penn and the private sector. Whether the end result is a technology license, an R&D alliance, or the formation of a new venture, PCI serves as a dedicated one-stop shop for commercial partnering with Penn.
Access the FY2025 Year in Review
#1
in licensing revenue 5th year in a row
26
Startups launched
>$591M
in investment capital raised or received by Penn affiliated startups
99
New patents awarded
Penn, BioNTech SE and Osage University Partners Launch Penn-BioNTech Innovative Therapeutics Seed Fund
The $50 million dedicated venture capital fund will invest in early-stage life science companies spun out of Penn. Learn more in the Philadelphia Inquirer, Global Corporate Venturing and Technical.ly Philly. For more information, please contact Anna Turetsky, PhD, General Partner, PxB Fund.
Penn Launches StartUP Fund
Penn announced the launch of its StartUP Fund, a new early-stage investment fund dedicated to supporting startup companies founded by Penn researchers and based on innovations created at the University. The fund will be managed by Penn’s Office of the Chief Investment Officer and backed by a $10M commitment from the University. Learn more and access the application here.
Penn Startups Raising Money
Discover over forty Penn startup companies raising capital in 2026. Read the list here.
PCI Showcases Precision Medicine During the JP Morgan Healthcare Conference
PCI hosted its annual Innovation @ Penn program at Wharton San Francisco concurrently with the annual JP Morgan Healthcare Conference. “Precision Medicine: Translating Discovery into Targeted Therapies” focused on innovative, personalized approaches to disease prevention and treatment.
Read more here.
Explore More
Access Penn’s New Inpart Portal
Discover select technologies on Inpart and connect with us for collaboration opportunities.
Access the portalRead the Latest News from PCI on LinkedIn
PCI’s New Technology LinkedIn Page
PCI recently launched a new LinkedIn page showcasing our technologies that are currently available for investment and partnership opportunities. Follow here.
Available Technologies
Find technology opportunities by sector or search:
Nanotechnology | Antibody | Optics & Photonics | Medical Devices | COVID-19 | Immunology | Oncology | Materials | Bioengineering | Neurodegenerative Diseases
View all technologies
Recent News
All NewsCapstan Therapeutics Acquired by AbbVie for $2.1B
Penn Medicine’s Kiran Musunuru Featured in The New York Times for Gene Therapy Breakthrough
Penn Engineering’s Liang Feng Conducts Promising Research on Nonlinear Neural Networks to Train AI on Lightspeed
New Tools for Treating Advanced Retinal Degenerations Developed by Penn Vet Researchers
Discover CAR T-cell technology at Penn
Our latest CAR T-cell enhancement portfolio features innovations poised to transform treatment efficacy with boosted cytokine activity/metabolism, streamlined manufacturing, and reduced T-cell exhaustion. Join us in turning lab discoveries into real-world impact through licensing opportunities with PCI.
Upcoming Events
All Events